Peptide Formulation

Peptide Formulation

Formulation development for peptide therapeutics addresses stability, delivery, and patient compliance challenges. This guide covers excipient selection, dosage forms, and formulation strategies.

Formulation Challenges

Challenge	Cause	Formulation Solution
Proteolysis	Enzymatic degradation	Protease inhibitors, cyclization
Oxidation	Met/Cys oxidation	Antioxidants, inert atmosphere
Aggregation	Hydrophobic interactions	Surfactants, pH optimization
Low solubility	Hydrophobic sequence	Co-solvents, pH adjustment
Instability at pH 7	Deamidation, isomerization	pH optimization
Immunogenicity	Aggregation, impurities	High purity,PEGylation

Excipient Guide

Buffers

Buffer	pKa	pH Range	Advantage	Disadvantage
Acetate	4.76	3.7–5.7	Volatile, MS-compatible	Limited pH range
Citrate	3.13, 4.76, 6.40	2.1–7.4	Wide range, GRAS	Metal chelation
Phosphate	7.20	6.2–8.2	Physiological pH	Calcium precipitation
Histidine	6.04	5.0–7.0	Protein stabilizer	Expensive
Tris	8.06	7.0–9.0	Common, stable	Temperature-dependent pH

Tonicity Adjusters

Agent	Concentration	Osmolality	Notes
NaCl	0.9%	308 mOsm	Most common
Mannitol	5%	278 mOsm	Non-ionic, stabilizer
Sucrose	5%	293 mOsm	Cryoprotectant
Sorbitol	5%	278 mOsm	Non-metabolized
Glycine	2%	267 mOsm	Stabilizer

Stabilizers

Stabilizer	Mechanism	Concentration	Use Case
Polysorbate 80	Surfactant	0.01–0.1%	Prevent aggregation
Polysorbate 20	Surfactant	0.01–0.05%	Prevent aggregation
BSA	Carrier protein	0.1–1%	Research formulations
Mannitol	Bulking agent	2–5%	Lyophilization
Sucrose	Cryoprotectant	5–10%	Freeze-thaw protection
Trehalose	Lyoprotectant	5–10%	Lyophilization

Antioxidants

Agent	Mechanism	Concentration	Notes
Ascorbic acid	Reducing agent	0.01–0.1%	May oxidize
BHT	Radical scavenger	0.01%	Lipophilic
Methionine	Oxygen scavenger	0.1–0.5%	Amino acid
EDTA	Metal chelator	0.01–0.05%	Prevents metal-catalyzed oxidation
Nitrogen purging	Oxygen removal	N/A	Processing step

Dosage Forms

Injectable Formulations

Formulation	Release	Dosing	Example
Solution	Immediate	Daily–weekly	Semaglutide
Suspension	Slow	Weekly–monthly	Insulin NPH
Depot (PLGA)	Sustained	Monthly–quarterly	Leuprolide
Albumin-bound	Extended	Weekly	Semaglutide
Fc-fusion	Extended	Weekly	Dulaglutide

Lyophilized Formulations

Component	Function	Typical %
Active peptide	Drug substance	0.1–5%
Bulking agent	Cake structure	2–10%
Cryoprotectant	Protect during freezing	5–15%
Buffer	pH control	10–50 mM
Tonicity agent	Isotonicity	0.9%

Oral Formulations

Technology	Mechanism	Bioavailability	Example
SNAC	pH modulation	~1%	Semaglutide oral
Enteric coating	Acid protection	1–5%	Investigational
Permeation enhancers	Tight junction	5–15%	Investigational
Nanoparticles	Lymphatic uptake	5–20%	Investigational

Formulation Development Process

Stage 1: Pre-formulation

1. Physicochemical characterization

   • Solubility profile (pH, co-solvents)
   • Stability in buffers
   • pKa determination
   • Hydrophobicity assessment

2. Compatibility studies

   • Excipient screening (binary mixtures)
   • Container/closure compatibility
   • Temperature cycling

Stage 2: Formulation Optimization

1. Design of Experiments (DoE)

   • Factor selection (pH, excipients, concentration)
   • Response surface methodology
   • Optimization criteria (stability, viscosity, clarity)

2. Accelerated stability

   • 40°C/75% RH (1–3 months)
   • 25°C/60% RH (3–6 months)
   • Stress conditions (freeze-thaw, agitation)

Stage 3: Scale-up

1. Process development

   • Mixing parameters
   • Filtration compatibility
   • Filling accuracy

2. Quality attributes

   • Critical quality attributes (CQAs)
   • Control strategy
   • Specifications

Lyophilization

Cycle Design

Step	Purpose	Typical Conditions
Freezing	Solidify matrix	-40°C, 2–4 hrs
Primary drying	Remove ice	-20°C, 0.1 mBar, 24–72 hrs
Secondary drying	Remove bound water	25°C, 0.01 mBar, 6–12 hrs

Excipient Selection for Lyophilization

Excipient	Tg’ (°C)	Role	Concentration
Trehalose	115	Lyoprotectant	5–10%
Sucrose	110	Lyoprotectant	5–10%
Mannitol	17	Bulking agent	2–5%
Glycine	2	Bulking agent	1–3%
PEG 4000	-8	Plasticizer	1–2%

Quality Attributes

Attribute	Acceptance	Method
Residual moisture	<2%	Karl Fischer
Cake appearance	Intact, uniform	Visual
Reconstitution time	<2 min	Visual/turbidimetry
pH	Within spec	pH meter
Purity	Within spec	HPLC

Stability Considerations

Degradation Prevention

Degradation	Prevention Strategy
Oxidation	Antioxidants, N₂ purge, amber vials
Deamidation	pH 4–5, low temperature
Aggregation	Surfactants, high concentration
Hydrolysis	pH 4–6, low temperature
Photodegradation	Amber vials, light protection

Container/Closure

Material	Compatibility	Use
Borosilicate glass	Excellent	Vials, ampoules
Type I glass	Excellent	Parenteral
Cyclic olefin polymer	Good	Pre-filled syringes
Cyclic olefin copolymer	Good	Vials
HDPE	Moderate	Research containers

Related Resources

• See Drug Delivery Systems for delivery technologies
• Review Formulation Excipients for excipient details
• Check Lyophilization for freeze-drying protocols
• Use Reconstitution Calculator for dilution calculations